TITLE

Langerhans’ cell histiocytosis of the spine in children with soft tissue extension and chemotherapy

AUTHOR(S)
Xin-Sheng Peng; Tao Pan; Li-Yan Chen; Gang Huang; Jin Wang
PUB. DATE
June 2009
SOURCE
International Orthopaedics;Jun2009, Vol. 33 Issue 3, p731
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract  The objectives of this paper were to look into the possible incidence of obvious soft tissue extension from Langerhans’ cell histiocytosis (LCH) of the spine in children and to evaluate the effects of chemotherapy for those patients. Eighteen patients with histopathological diagnosis of LCH were reviewed and nine with obvious paravertebral soft tissue extension were included in this study. Soft tissue extension was involved in the spinal canal and/or around the vertebral body in eight cases and posterior involvement was prevalent in one case. Eight patients experienced neurological symptoms. All received chemotherapy and one had surgical treatment. The mean follow-up time was 30.3 months. Soft tissue extension disappeared completely in all patients. No clinical evidence of disease was observed at the most recent follow-up. The incidence of LCH of the spine in children with obvious soft tissue extension was up to 50%. Chemotherapy is safe and effective, and surgical decompression was probably not necessary for most patients.
ACCESSION #
41427074

 

Related Articles

  • Multifocal Intraparenchymal Langerhans’ Cell Histiocytosis Concomitant With an Arachnoid Cyst in a Child: Case Report and Review of the Literature. Wang, Yong; Qiu, Bo; Li, Ping; Cheng, Peng; Li, Guangyu; Li, Xinguo; Xu, Hongtao; Wang, Yunjie // Journal of Child Neurology;Jun2012, Vol. 27 Issue 6, p767 

    Langerhans’ cell histiocytosis is a disease usually found in children and characterized by idiopathic proliferation of histiocytes in the reticuloendothelial system. Intracranial Langerhans’ cell histiocytosis presenting as multifocal intraparenchymal lesions is very rare. In this...

  • Histopathologic features of a resolving orbital Langerhans cell histiocytosis. Zyl, Tavé; Stagner, Anna; Jakobiec, Frederick; Yoon, Michael // Graefe's Archive of Clinical & Experimental Ophthalmology;Dec2015, Vol. 253 Issue 12, p2341 

    No abstract available.

  • Results of Treatment with 2-Chlorodeoxyadenosine (2-CDA) in Multiple Reactivations or Refractory Langerhans Cell Histiocytosis. Ansari, Shahla; Miri-Aliabad, Ghasem; Arjmandi-Rafsanjani, Khadijeh // Zahedan Journal of Research in Medical Sciences;Jan2014, Vol. 16 Issue 1, p94 

    Background: Langerhans cell histiocytosis (LCH) is the most common type of histiocytosis and characterized by abnormal proliferation and excess accumulation of inflammatory and langerhans cells at various tissue sites. Clinical manifestations are variable, ranging from spontaneously regressing...

  • THREE CASES OF LANGERHANS CELLS HISTIOCYTOSIS. A. B., Izzat Abdulla; A. K., Meera Mohaideen // Malaysian Journal of Medical Sciences;Jan2008 Supplement, p56 

    Introduction: Langerhans' cell histiocytosis (LCH) is a rare multisystemic disorder with abnormal proliferation of histiocytes, affecting mostly children of both sexes. It can present as Localized eosinophilic granuloma (70%) or disseminated form (30%). Symptoms and findings vary depending on...

  • Complement Factor C7 Contributes to Lung Immunopathology Caused by Mycobacterium tuberculosis. Welsh, Kerry J.; Lewis, Cole T.; Boyd, Sydney; Braun, Michael C.; Actor, Jeffrey K. // Clinical & Developmental Immunology;2012, p1 

    Mycobacterium tuberculosis (MTB) remains a significant global health burden despite the availability of antimicrobial chemotherapy. Increasing evidence indicates a critical role of the complement system in the development of host protection against the bacillus, but few studies have specifically...

  • Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis. Blair, Hannah; Scott, Lesley // Drugs;Jan2015, Vol. 75 Issue 1, p91 

    Delamanid (Deltyba), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and...

  • Advancing the safe and appropriate use of oral chemotherapy agents. Goodin, Susan // American Journal of Health-System Pharmacy;5/1/2007 Supplement, Vol. 64, pS3 

    The article discusses various reports published within the issue, including one on the mechanisms of action, uses and potential for drug interactions of the oral chemotherapeutic agents and another on the side effects of oral chemotherapy.

  • Histopathological features of gastrointestinal mucosal biopsy specimens in children with epidermolysis bullosa. Shah, N.; Freeman, E.; Martinez, A.; Mellerio, J.; Smith, V. V.; Undley, K. J.; Sebire, N. J. // Journal of Clinical Pathology;Jul2007, Vol. 60 Issue 7, p843 

    The article discusses a study on the gastrointestinal mucosal histopathological features in children with epidermolysis bullosa (EB). The study shows that patients may exhibit inflammatory changes, iron-laden macrophages and a florid increase in colonic mucosal lamina propria karyorrhectic...

  • The Nikolas Symposia and histiocytosis. Beverley, Peter C. L.; Egeler, R. Maarten; Arceci, Robert J.; Pritchard, Jon // Nature Reviews Cancer;Jun2005, Vol. 5 Issue 6, p488 

    Histiocytoses are a group of rare diseases that involve histiocytes (literally tissue cells (Greek), but in reality tissue-resident macrophages and dendritic cells), which are derived from bone-marrow stem cells. Histiocytoses pose problems similar to those of other rare diseases of childhood....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics